Cite

    Patil, V. et al. (2020). Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. Lancet. 8 (9), pp. e1213-e1222. [Online].